Better Science, Better Health
“Better Science, Better Health” was created by Vital Transformation to advance healthcare by connecting stakeholders worldwide and translating complex research, regulation, and evidence into clear, accessible knowledge.
“Better Science, Better Health” is an educational initiative created by Vital Transformation to support learning and collaboration across the healthcare community. Its purpose is to help all stakeholders in healthcare—such as patients, healthcare professionals, regulators, researchers, and industry—better understand the health care scene, new ways of developing and approving medicines.
Better Science, Better Health explains regulatory approaches, new types of scientific evidence, and the use of real-world data. It will also help make the research produced by the Vital Transformation team (www.vitaltransformation.com) more accessible to a broad audience.
What are we up to?
Petra & Gwen are on a roll with their new podcast series... Episode #2 will be released soon!
Follow us on Youtube or linkedIn
Listen to episode #1 …
Check it out
VT went to Glasgow
At ISPOR Europe 2025 in Glasgow, Duane and Ben recorded a series of Vital Health Podcast conversations on how Europe can deliver faster, evidence-based access to innovative therapies while keeping health systems sustainable.
All good and well, but want to see how we build our booth?
Video & pics …
VT was part of Trials@Home
The Trials@Home consortium explored the opportunities of moving clinical trials from the traditional clinic setting to the participant’s immediate surroundings.
Petra and Gwen were the VT forces in the project and what did they do?
Video …
Interesting stuff
Better Science, Better Health The Podcast #4 – The Medicine Investment Puzzle
In this episode of the Better Science Better Health podcast, Gwen and Petra take on another jargon-heavy stretch of the Vital Health Podcast with Steve Potts and Duane Schulthess and unpack what is really being said about biotech financing, drug development, and the policy rules shaping investment.Listen here …
Better Science, Better Health The Podcast #3 – The Key Ingredients Behind Generic Shortages
In this episode, Gwen and Petra take on a Vital Health Podcast best-of about generic drug shortages and supply chain risk. They unpack the healthcare terms at the center of the discussion - generics, biologics, biosimilars, APIs, and PBMs - and explain how pricing pressure, manufacturing concentration, and reimbursement dynamics can affect whether medicines actually reach patients. Listen here …
Better Science, Better Health The Podcast #2 – The Hidden Language of Drug Value
In this first episode of the Better Science Better Health podcast, Gwen and Petra press pause on a clip from the Vital Health Podcast and unpack what is really being said, without the policy fog or economist smoke machine.Listen here …
NEW!! Better Science, Better Health The Podcast – How The Prisoner’s Dilemma Shapes Drug Pricing
In this first episode of the Better Science Better Health podcast, Gwen and Petra press pause on a clip from the Vital Health Podcast and unpack what is really being said, without the policy fog or economist smoke machine.Listen here …
Blog: What is the Inflation Reduction Act (IRA) and what are the effects?
Inflation Reduction Act (IRA) medicine pricing rules are reshaping therapy development and financing, with ripple effects for patient access. Read More …
Vital Health Podcast
Listen to the Vital Health Podcast
Visit our youtube channel to view all of our videos.
Newsletter
Sign up for our newsletter and receive our latest news
Latest research from Vital Transformation
Follow us
Archive
VT went to Glasgow!
VT went to Glasgow
At ISPOR Europe 2025 in Glasgow, Duane and Ben recorded a series of Vital Health Podcast conversations on how Europe can deliver faster, evidence-based access to innovative therapies while keeping health systems sustainable.
All good and well, but want to see how we build our booth?
Video & pics …
IRA
Blog: What is the Inflation Reduction Act (IRA) and what are the effects?
Inflation Reduction Act (IRA) medicine pricing rules are reshaping therapy development and financing, with ripple effects for patient access. Read More …
FDA vs EMA Approval: Why Decisions Can Differ
FDA vs EMA Approval: Why Decisions Can Differ
A drug approved by the US Food and Drug Administration (FDA) may not be approved by the European Medicines Agency (EMA) due to differences in regulatory frameworks, evidence expectations, and risk tolerance — not because one decision is “right” or “wrong”.
Read More …